This strategy admittedly comes at the sacrifice of finding mutation-specific vulnerabilities (such as SYK in FL3-mutant AML), but at the potential benefit of finding shared targets applicable to a greater number of patients. This evidence concerns the gene SYK and acute myeloid leukemia.